Beijing Tongrentang Co., Ltd

600085

CNE000000R69

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 06:00:00 2024-04-24 pm EDT			5-day change	1st Jan Change
40.83 ^CNY	-0.75%		-2.48%	-23.97%

Mar. 28	Beijing Tongrentang Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Mar. 06	China Approves Tong Ren Tang Group's Clinical Trial of Heart Failure Drug	MT

Beijing Tongrentang Co., Ltd Announces Earnings Results for the Year 2017

March 29, 2018

Beijing Tongrentang Co. Ltd. announced earnings results for the year 2017. For the period the company reported basic earnings per share were CNY 0.742 and weighted average return on net assets was 12.55%.

Latest news about Beijing Tongrentang Co., Ltd

Beijing Tongrentang Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
China Approves Tong Ren Tang Group's Clinical Trial of Heart Failure Drug	Mar. 06	MT
Beijing Tongrentang Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-30	CI
Chinese listed firms used endangered animal parts as ingredients -report	23-10-23	RE
Three listed Chinese firms used endangered animal parts as ingredients- report	23-10-22	RE
China's crackdowns rewrite investors' private sector playbook	23-08-17	RE
Beijing Tongrentang Co., Ltd Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-04	CI
Beijing Tongrentang Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-28	CI
Beijing Tongrentang Co., Ltd announced that it expects to receive CNY 33.345 million in funding from Jianzhijia Pharmaceutical Chain Group Co., Ltd.	22-12-28	CI
Beijing Tongrentang Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-27	CI
Beijing Tongrentang Co., Ltd(XSSC:600085) added to S&P Global BMI Index	22-09-19	CI
Beijing Tongrentang Co., Ltd(XSSC:600085) added to FTSE All-World Index	22-09-19	CI
Beijing Tongrentang Co., Ltd Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-30	CI
MSCI to add 13 securities to its ACWI index, and delete 8 securities	22-08-11	RE
Beijing Tongrentang Co., Ltd(SHSE:600085) added to SSE 180 Index	22-06-13	CI
Beijing Tongrentang Co., Ltd(SHSE:600085) added to Shanghai Stock Exchange 180 Value Index	22-06-13	CI
Beijing Tongrentang Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-29	CI
Beijing Tongrentang Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-25	CI
Beijing Tongrentang Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2021	21-10-29	CI
Beijing Tongrentang Co., Ltd Reports Earnings Results for the Half Year Ended June 30, 2021	21-08-25	CI
China stocks end lower as healthcare, tech firms tumble	21-07-06	RE
China stocks fall on healthcare slump; Hong Kong down	21-07-06	RE
Beijing Tongrentang Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2021	21-04-29	CI
Beijing Tongrentang Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2020	21-03-29	CI
Beijing Tongrentang Co., Ltd(XSSC:600085) dropped from S&P Global BMI Index	20-12-21	CI

Chart Beijing Tongrentang Co., Ltd

Duration

Period

More charts

Company Profile

BEIJING TONGRENTANG CO., LTD is a China-based company principally engaged in the production and sales of traditional Chinese patent medicines. The Companyâs main products consist of liuwei dihuang series, tongren dahuoluo series, tongren niuhuang qingxin series, angong niuhuang series and donkey-hide gelatin series. The Company distributes its products under the brand of Tongrentang. The Company is also involved in the operation of Tongrentang drug stores. The Company distributes its products in domestic market and to overseas markets.

Sector

Pharmaceuticals

Calendar

2024-04-29 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Beijing Tongrentang Co., Ltd

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

40.83 CNY

Average target price

53.25 CNY

Spread / Average Target

+30.43%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
BEIJING TONGRENTANG CO., LTD	-23.97%	7.79B
NOVO NORDISK A/S	+24.17%	562B
JOHNSON & JOHNSON	-6.33%	358B
MERCK & CO., INC.	+19.90%	322B
ABBVIE INC.	+7.95%	297B
ASTRAZENECA PLC	+13.45%	219B
NOVARTIS AG	+6.04%	199B
ROCHE HOLDING AG	-10.51%	196B
PFIZER, INC.	-12.26%	149B
AMGEN INC.	-6.47%	146B

Other Pharmaceuticals